







中药配方颗粒行业开创者与领跑者
TIANJIANG PHARMACEUTICAL CO., LTD.

- PIONEER AND LEADER
IN CHINESE HERBAL EXTRACT GRANULES

JIANGYIN TIANJIANG
PHARMACEUTICAL CO.,LTD

天江通讯

Tianjiang Newsletter

2021年8-9月 Aug – Sep 2021

CONTENTS

Tianjiang News

Promote industrial development with technological innovation-Tianjiang Pharmaceutical participates in the 2021 Service Trade Fair and presents Tianjiang style / 3

Tianjiang Pharmaceutical was awarded the "Wuxi City's Famous Export Brand" / 4

New Standards, New Concepts, New Patterns-The Symposium on Consistency Evaluation of Chinese Medicine Extract Granules and National Standard Application was successfully held / 5 The international academic layout of Tianjiang Pharmaceutical-Federation of Chinese Medicine and Acupuncture societies of Australia successfully held online academic activities / 6

Sinopharm Group News

The first meeting of the International Forum on New Crown Vaccine Cooperation was held! Chinese vaccine companies make a promise! / 7

China-Africa Economic and Trade Expo: International vaccine cooperation / 8 writes a new chapter in China-Africa friendship

International exchanges create a better future—China Traditional Chinese medicine Holdings Co,,, Ltd / 9

Industry News

The State Food and Drug Administration approved, promulgated and publicized the National Drug Standards for Chinese Medicine Formula Granules / 10
Best documentary! Chinese medicine documentary "Jin Huachang" won the New York State International Film Festival / 11

Tianjiang Quality Control

Tianjiang Quality Control System - Quality control of raw medicinal materials $\ \ /\ 13-15$

Professional development of Chinese medicine

TCM treatment of polycystic ovary syndrome / 16
The immunological pathogenesis of vitiligo / 17
TCM treatment of melasma / 18
TCM diagnosis and treatment of peptic ulcer / 19

Tianjiang's Products

Hei Zhi Ma Wan / 20

Introduction of Tianjiang Pharmacetical / 21

目录

天江资讯

以科技创新促产业发展——2021服贸会现天江风采 / 3 天江药业荣获"无锡市重点培育和发展的国际知名品牌" / 4 新标准、新理念、新格局——中药配方颗粒—致性评价和国标应用研讨会顺 利召开 / 5

天江药业之国际化学术布局——澳洲中医药针炙学会顺利举办线上学术活动 / 6

集团简讯

新冠疫苗合作国际论坛首次会议召开——中国疫苗企业庄严承诺!/7中非经贸博览会:疫苗国际合作书写中非友好新篇章/8中非湘会谋发展 国际交流赢未来——中国中药/9

行业简讯

国家药监局批准颁布及公示中药配方颗粒国家药品标准最近进展 / 10 最佳纪录片! 中医药纪录片《金华昌》纽约州国际电影节摘冠 / 11

天江品控

天江品质控制体系之药材质量控制——药材基地建设 / 12-15

中医药的专业性发展

多囊卵巢综合征中医中药治疗 / 16 白癜风的免疫学发病机制 / 17 黄褐斑的中医治疗 / 18 消化性溃疡的中医诊疗 / 19

天江产品

黑芝麻丸 / 20

天江简介 / 21

Promote industrial development with technological innovation-

Tianjiang Pharmaceutical participates

in the 2021 Service Trade Fair and presents Tianjiang style





2021 China International Service Trade Fair ·2021 CIFTIS · International Think Tank Summit on TCM Health Industry was held in Beijing. Leaders from the State Administration of Traditional Chinese Medicine, Beijing Municipal Government, Beijing Municipal Health Commission, and Beijing Administration of Traditional Chinese Medicine attended the forum and delivered speeches.

At the same time, gathering the wisdom of representatives of governments, enterprises, universities, research institutions and the media to build a communication platform for the entire industry chain of traditional Chinese medicine at home and abroad, and comprehensively promote the development of traditional Chinese medicine and the development of national medicine all around the world.

It is reported that the International Think Tank Summit Forum of the Chinese Medicine and Health Industry has been held during the "Service Trade Fair" for three consecutive years and has become one of the key forums in the Chinese medicine section. Hu Qifei, general manager of Jiangyin Tianjiang Pharmaceutical Co., Ltd., gave a keynote speech entitled "Promoting High-quality Development of Traditional Chinese Medicine Industry with Technological Innovation".

General Manager Hu Qifei introduced the basic situation of Tianjiang from three aspects: development history, technological innovation, and social responsibility. Tianjiang has always been committed to the research, production and sales of Chinese medicine formula granules. At the same time, it also actively promotes the development of the Chinese medicine industry through personnel training and technological innovation. The innovation capability has reached a "new" level, the national standard has "new" achievements, the internationalization has entered a "new" journey, and development of a certain kind of formula products has achieved "new" breakthroughs. Mr. Hu said that China's traditional Chinese medicine is based on the source of Chinese civilization, the source of Chinese medicine theory, and the source of Shennong's herbal medicine. It is supported by conceptual innovation, technological innovation, and product innovation. Through the efforts of the Chinese medicine industry, it will surely be able to accelerate its modernization, standardization, and internationalization.

Tianjiang Pharmaceutical was awarded the "Wuxi City's Famous Export Brand"

In order to enhance the international competitiveness of Wuxi's independent brands and promote the high-quality development of foreign trade, the Wuxi Municipal Bureau of Commerce has launched the selection of the "Wuxi City's Famous Export Brand". After preliminary review, reexamination, cross-departmental solicitation of opinions and public announcements, the TIANJIANG brand of Tianjiang Pharmaceutical was awarded the "Wuxi City's Famous Export Brand".



New Standards, New Concepts, New Patterns-The Symposium on Consistency Evaluation of Chinese Medicine Extract Granules and National Standard Application was successfully held





On September 25, the "2021 Working Conference of the Hospital Pharmacy Branch of the Chinese Society of Chinese Medicine and the Symposium on the Consistency Evaluation of Chinese Medicine Formula Granules and the Application of National Standards" was successfully held in Beijing. The conference was co-hosted by the Hospital Pharmacy Branch of the Chinese Society of Chinese Medicine and Beijing Pharmaceutical Association, and co-organized by Jiangyin Tianjiang Pharmaceutical Co., Ltd. This conference brought together more than 20 pharmacy and clinical experts from Chinese medicine hospitals and general hospitals from all provinces municipalities across the country. This meeting took the form of a combination of online and offline, and discussed key issues such as the consistency evaluation of formula particles and the implementation of national standards.

According to Hu Qifei, general manager of Jiangyin Tianjiang Pharmaceutical Co., Ltd., Tianjiang Pharmaceutical, based on its own perfect scientific research system, promotes industry societies to carry out the evaluation project of consistency between classic decoctions and formula granules, and devotes itself to the formulation of national standards. At present, Tianjiang has undertaken 48 of the 196 national standards that have been publicized by the country, which fully demonstrates Tianjiang Pharmaceutical's corporate responsibility as the pioneer and leader in the industry of traditional Chinese medicine formula granules.

The international academic layout of Tianjiang Pharmaceutical-Federation of Chinese Medicine and Acupuncture societies of Australia successfully held online academic activities



On September 5, 2021, the online international academic seminar "Research and New Progress in Infertility in Traditional Chinese Medicine" was successfully held. This academic forum was organized by the Australian National Federation of Chinese Medicine and Acupuncture Societies, undertook by the Australian National Federation of Chinese Medicine and Acupuncture Societies Victoria Branch (FCMA-VIC), and co-organized by Jiangyin Tianjiang Pharmaceutical Co., Ltd.

The conference was opened by Lin Ziqiang, chairman of the Australian National Federation of Chinese Medicine and Acupuncture Societies, and 11 domestic and foreign infertility Chinese medicine experts were invited to give online lectures. Among them, Professor Liang Dongyun from the United States, Professor Lian Fang from the Affiliated Hospital of Shandong University of Traditional Chinese, Dr. Chen Fangyang from Hong, Professor Zhou Shaohu of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Dr. Han Yonggang, Dr. Sun Yun from the United Kingdom, Dr. Wang Huimin from Hong Kong, Shan Yuetao, Liu Yanyan from Australia all gave wonderful speeches and shared their valuable experience in TCM treatment.

The online academic exchanges lasted 12 hours in total. Experts focused on issues related to infertility in terms of clinical, treatment, prescription and medication. Simultaneous translation in Chinese and English was used in this academic exchange, and the attending Chinese medicine practitioners said that they have benefited a lot. After the meeting, the participants remained enthusiastic, interacting with experts in the exchange group, and watched the replay of the meeting repeatedly.

The first meeting of the International Forum on New Crown Vaccine Cooperation was held! Chinese vaccine companies make a promise!



On the evening of August 5, the first meeting of the International Forum on New Coronary Vaccine Cooperation was held by video. Representatives of various countries, representatives of the United Nations, international organizations, and representatives of related enterprises conducted in-depth discussions on the theme of "strengthening international cooperation in vaccines and advancing the fair and reasonable distribution of global vaccines". The meeting reached a five-point consensus, and 23 participating countries also jointly issued a joint statement on the International Forum on New Coronary Vaccine Cooperation.

Liu Jingzhen, Chairman of Sinopharm Group, spoke at the forum on behalf of Chinese vaccine companies. Companies from various countries have agreed to establish partnerships to expand vaccine production and supply; to reach a cooperation intention of more than 1.5 billion doses of vaccines in 2021, and Chinese companies will provide partners in the form of finished products or original solutions. The participating companies all attach great importance to the joint production of vaccines. They have carried out joint production with companies from 8 countries and reached cooperative production agreements with many countries. As the only group company in the world that has independent intellectual property rights and has developed three new crown vaccines on two technical routes, Sinopharm Sinopharm is the only company in the world. Sinopharm Group will continue to benefit people in more countries and regions with high-quality vaccines, and contribute to helping the world overcome the new crown epidemic at an early 7 date!

China-Africa Economic and Trade Expo: International vaccine cooperation writes a new chapter in China-Africa friendship



On September 26, the second China-Africa Economic and Trade Expo opened in Changsha, Hunan. In the "China's Anti-epidemic Assistance" section of the "China-Africa Economic and Trade Cooperation Achievements Exhibition", the organizing committee introduced the results of China's Sinopharm's vaccine assistance to Africa.

Sinopharm Group has carried out anti-epidemic material export and foreign aid work in 51 African countries. Among them, 6,541,100 pieces of Chinese government-aided anti-epidemic materials were implemented, and 285.29 million pieces were exported, with a total value of 48,546,700 US dollars. In terms of international vaccine cooperation, 55,953,900 doses of national medicine vaccines were shipped to 36 African countries, and Chinese government vaccine assistance tasks were performed in 29 African countries.

Sinopharm continues to prioritize African countries for vaccine supply, and at the same time actively selects a team of medical experts to expand the scale of aid and export of anti-epidemic materials, and firmly supports Africa's fight against the epidemic. It has won high praise from the governments and people of African countries, writing a new chapter for China-Africa friendship, and injecting new impetus into global cooperation in the fight against the epidemic.

International exchanges create a better future





At this China-Africa Economic and Trade Expo, the exhibition area of China Traditional Chinese Medicine Holding Co., Ltd. focused on the company's national base construction and medicinal resources layout results, and exhibited Chinese medicine formula granules, Chinese patent medicines, Chinese medicine decoction pieces, and key products of Chinese medicine for general health., Such as: Tianjiang Pharmaceutical and Yifang Pharmaceutical's extract granule products, anti-epidemic new medicine Huashibaidu Granules, Taiji Huoxiang Zhengqi Liquid, Xianling Gubao Capsules and other Chinese patent medicines, and Yue Jian Ben Cao, Yifang Siji, Taiji Ejiao, etc. A series of large health products attract many guests and audiences to come to visit and experience, discuss cooperation.

Chairman Wu Xian focused on the layout of the entire industrial chain of Chinese medicine under the Sinopharm Group, and the brand structure of China Traditional Chinese Medicine with the "Longyin Chinese Medicinal Materials" brand as the core and multi-brand extension development. Including the development results and products of the whole industry chain such as the cultivation of Chinese medicinal materials, Chinese medicinal pieces, Chinese medicinal formula granules, Chinese patent medicines and Chinese medicine for health. It fully demonstrates the leading position of China Traditional Chinese Medicine as "the world's leading brand in the traditional Chinese medicine industry" and "the world's largest traditional Chinese medicine manufacturing industry cluster".

a

The State Food and Drug Administration approved, promulgated and publicized the National Drug Standards for Chinese Medicine Formula Granules

The State Food and Drug Administration approved, promulgated and publicized the National Drug Standards for Chinese Medicine Formula Granules

Approved by the National Medical Products Administration, the first batch of 160 Chinese medicine formula granules national drug standards have been officially promulgated and will be officially implemented on November 1, 2021. In addition, the second batch of 36 Chinese medicine formula granules national drug standards are being announced. The first two batches of national formula granule standards total 196, of which 48 product standards declared by Jiangyin Tianjiang Pharmaceutical Co., Ltd. have been approved.

The overall situation of the national standard:

- ➤ On August 5, 2016, National Pharmacopoeia Commission "Technical Requirements for Quality Control and Standard Establishment of Chinese Medicine Formula Granules (Soliciting Opinions)"
- ➤ On April 11, 2018, the first national standard review meeting of the National Pharmacopoeia Commission
- ➤ On November 8, 19, the State Food and Drug Administration "Technical Requirements for Quality Control and Standard Establishment of Chinese Medicine Formula Granules (Soliciting Opinions)"
- ➤ On November 8, 19, the first batch of 160 varieties of Chinese medicine formula granules national standards was announced by the Pharmacopoeia Commission
- ➤ On February 10, 21, the State Food and Drug Administration "Technical Requirements for Quality Control and Standard Establishment of Chinese Medicine Formula Granules", "Announcement on Ending the Pilot Work of Chinese Medicine Formula Granules"
- ➤ On April 29, 2021, the first batch of 160 varieties of Chinese medicine formula granules national standards was officially released
- ➤ On April 30, 2021, the second batch of 36 varieties of Chinese medicine formula granules national standards publicized by the Pharmacopoeia Commission
- ➤ On August 27, 2021, "Announcement on the Acceptance and Evaluation of National Standard Application Materials for Chinese Medicine Formula Granules (Phase 1, 2021)"

Best documentary! Chinese medicine documentary "Jin Huachang" won the New York State International Film Festival



"Jin Huachang" won the New York State International Film Festival (NYSIFF) 2021 Best Documentary Award!

The New York State International Film Festival this year received a total of 346 works from 23 countries and regions around the world. After fierce competition, 33 outstanding works were selected. On this basis, the selection was made again, and the 2021 Best Documentary Award was born!

Jinhuachang is a grocery store and Chinese medicine clinic that appeared in the Great Gold Rush a hundred years ago. It is located in the small town of John Day in Oregon, USA.

Wherever there are Chinese, there is traditional Chinese medicine. The film reveals the historical past that has been covered in dust by the years, vividly tells the legend of overseas Chinese who have worked hard to start a business, and shows the spirit of the great doctor of the world. What is oncoming is a xinglin pennant that will always fly in North America.

Director Huan Yiping said, "This film is a segment of the journey of exploring and discovering Chinese medicine overseas with Professor Zhao Zhongzhen's team over the past few years, and it is also a part of the large-scale international Chinese medicine humanities documentary "Materia Medica Without Borders."

11

Tianjiang Quality Control System


Chinese medicine extract granules, using standardized processed Chinese medicine pieces as raw materials, are made with modern pharmaceutical technology such as scientific extraction, low-temperature concentration, instantaneous drying technology, etc., under the guidance of Chinese medicine theory,

In order to ensure the stability, uniformity and effectiveness of the product quality of traditional Chinese medicine formula granules, Tianjiang Pharmaceutical Co., Ltd. carries out quality control throughout the whole process from the source of the medicinal materials to the final product, including:

- (1) Quality control of medicinal materials
- (2) Quality control of decoction pieces
- (3) Quality control of preparation process
- (4) Production monitoring
- (5) Finished product quality control
- (6) Enterprise quality traceability system
- (7) Quality standards

"Tianjiang Newsletter" will continue to transmit Tianjiang quality control information. In this issue, we will share the first step of quality control -- quality control of medicinal materials

Quality control of raw medicinal materials



Aiming at the endogenous factors that affect the safety of traditional Chinese medicine, the company has strengthened the research on the basis, processing and production technology to ensure its safety and effectiveness. For the raw materials and finished products of traditional Chinese medicine formula granules, inductively coupled plasma mass spectrometry technology is used to detect the limit of heavy metals and harmful elements, and technical methods such as gas chromatography and high performance liquid chromatography are used to detect pesticide residues, sulfur dioxide residues, and aflatoxin Detection.

After a general survey of multiple batches of samples of all varieties, more than 100 varieties that need to be monitored for heavy metals and harmful elements, pesticide residues, sulfur dioxide and aflatoxin were screened out, and they were listed as key research and monitoring varieties, and targeted research was carried out. Investigate, study the reasons for its occurrence, explore effective prevention and control methods and measures, and establish internal control standards for the safety of key varieties from raw materials to finished products based on this. This work fills the gap in the research on quality standards related to the safety indicators of Chinese medicine formula granules in China.

Security target control

Heavy metal limits control

- ◆ Optimizing the origin of raw medicinal materials, and determining the safe origin of raw medicinal materials through the inspection of the soil, water quality, and air environment of the place of production and the detection and comparison of collected samples.
- ◆ To study the accumulation characteristics of heavy metals in different medicinal materials and the accumulation characteristics of heavy metals in different parts of plants (animals), to guide the selection of base planting varieties and the evaluation of medicinal parts.
- ◆ Include heavy metals in routine inspection items, refer to the limit standards for heavy metals in various countries, establish internal control standards that meet international requirements, and implement internal control of raw materials and routine inspections of finished products.

Pesticide residue control

- ◆ Choose a suitable location, establish a medicinal material production base or a cooperative production base, and control the use of pesticides by strengthening field management.
- ◆ Develop internal control standards for pesticide residues, and conduct pesticide residue testing before production. Any unqualified product must be re-assessed for the origin of the variety.

Security target control

Aflatoxin control

- ◆ Build a medicinal material production base or cooperation base, and formulate standard operating procedures for processing at the origin. For example, when jujube kernels are removed from the production area, the method of long-term soaking and pounding to remove the pulp is generally used. During this period, it is easy to breed mold, causing aflatoxin to exceed the standard. After finding the source, the company established a cooperative base, requiring processing in strict accordance with the provided standard operating procedures, such as harvesting mature fruits and peeling meat by hand.
- ◆ For the varieties that are not easy to preserve, arrange the production of new materials according to the season. For example, Corydalis yanhusuo is often moldy due to untimely drying during processing. In response to this, the company requires the suppliers of the cooperative base to arrange for drying immediately after cooking when the suppliers of the cooperative base produce new processing, and the company arranges the production of materials in a timely manner.

Sulfur fumigation

◆ Sulfur fumigation is one of the common methods of traditional Chinese medicinal materials to prevent mildew and insects. Therefore, excessive sulfur in medicinal materials sometimes occurs. According to the results of Tianjiang Pharmaceutical's general survey, more than 60 varieties of sulfur dioxide that easily exceed the standard are considered as key monitoring. With reference to international sulfur dioxide detection methods and standards, strict internal control standards have been established.

TCM treatment of polycystic ovary syndrome

Polycystic ovary syndrome is one of the common gynecological endocrine diseases in clinic. In recent years, its incidence has been on the rise, and its cause has not yet been fully elucidated. Current research believes that it may be due to the interaction of certain genetic genes and environmental factors. Tianjiang Pharmaceutical invited Yang Sheng, director of the Department of Gynecology, Fuzhou Hospital of Traditional Chinese Medicine, to give us a lecture on "Polycystic Ovarian Syndrome Treatment in Traditional Chinese Medicine".

Sheng YANG:

Graduated from the Medical Department of Fujian University of Traditional Chinese Medicine. Engaged in the diagnosis and treatment, scientific research, and teaching of Chinese medicine in gynecology for more than 30 years. He was taught by Professor Luo Yuankai, the sacred hand of Lingnan Gynecology, and Professor Sun Tancun, the sixth generation descendant of Sun's Gynecology.

Areas of expertise: Gynecological menstrual diseases (menorrhagia, oligomenorrhea, early and late menstruation), dysmenorrhea, amenorrhea, threatened abortion, pregnancy disease, postpartum disease, infertility, menopausal syndrome, gynecological inflammation, obesity, facial acne, chloasma Spot and so on.

16

The immunological pathogenesis of vitiligo

Vitiligo is a relatively common skin disease. Most of these diseases are caused by the loss of skin melanocyte function. The specific cause is not yet clear. Vitiligo is relatively harmful and will have a huge impact on the patient's personal image and psychology. In this issue, Tianjiang Pharmaceutical invited Yang Ji, director of Zhongshan Hospital Affiliated to Fudan University, to give us a lecture on the immunological pathogenesis of vitiligo, introducing the current research progress on the immunological pathogenesis of vitiligo.



Ji YANG

- Director of Dermatology Department, Zhongshan Hospital Affiliated to Fudan University
- Executive member of the Dermatologist Branch of the Chinese Medical Doctor Association
- Vice Chairman of the Skin Immunity Professional Committee of Shanghai Society of Immunology
- Member of the Skin Rehabilitation Professional Committee of the Chinese Society of Disease Rehabilitation Medicine

TCM treatment of melasma

Melasma is a chronic, acquired skin disease with increased facial pigmentation. The lesions are yellowish-brown or dark brown patches, often symmetrically distributed on the cheeks, and can also involve the periorbital, forehead, upper lip and nose, and the edges are generally more obvious.

There are no subjective symptoms and general discomfort. The depth of the spots is related to the season, sun exposure, and endocrine factors. The incidence rate of Asian women of childbearing age is as high as 30%, and it is easy to relapse and difficult to cure. At present, TCM treatment has unique advantages in clinical practice. Tianjiang Pharmaceutical has specially invited Professor Min Zhongsheng, the chief physician of Jiangsu Provincial Hospital of Traditional Chinese Medicine, to share with you the "Traditional Chinese Medicine Treatment of Chloasma" based on his many years of clinical experience. Please stay tuned.

Zhong-sheng Min:

- Chief physician, professor, master tutor
- Leader and former director of the Department of Dermatology, Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Former member of the Standing Committee of the Dermatology Branch of the Chinese Society of Chinese Medicine
- Member of the Standing Committee of the Dermatology and Venereology Professional Committee of the Chinese Society of Integrative Medicine
- Chairman of the Dermatology Professional Committee of Jiangsu Society of Integrative Medicine
- Editorial member of Journal of Clinical Dermatology, Chinese Journal of Integrated Traditional Chinese and Western Medicine on Dermatology and Venereology
- Editorial Board Member of Chinese Journal of Dermatology

TCM diagnosis and treatment of peptic ulcer

Peptic ulcer mainly refers to chronic ulcers that occur in the stomach and duodenum. It is a frequently-occurring and common disease. There are various factors in the formation of ulcers. Among them, the digestive effect of acidic gastric juice on the mucosa is the basic factor in the formation of ulcers, hence the name. Tianjiang Pharmaceutical specially invited Liu Zhuhua, director of the Affiliated Hospital of Shanxi University of Traditional Chinese Medicine to teach us "Diagnosis and Treatment of Peptic Ulcer in Traditional Chinese Medicine".




Zhu-hua LIU:

- Chief physician and postgraduate tutor of the Spleen and Stomach Department of the Affiliated Hospital of Shanxi University of Traditional Chinese Medicine
- Member of Spleen and Stomach Disease Branch of Chinese Society of Chinese Medicine
- Executive member of the Digestive Disease Professional Committee of China Association of Chinese Materia Medica
- The fourth batch of outstanding TCM clinical personnel training objects in the country
- The second batch of young and middle-aged TCM clinical leading talents in Shanxi Province




For more lecture details, please pay attention to Tianjiang Pharmaceutical's public account

Tianjiang Homology Formulas ——Hei Zhi Ma Wan



Jiangyin Tianjiang Pharmaceutical Co., Ltd.



Jiangyin Tianjiang Pharmaceutical Co., Ltd. was founded in 1992 and is the first enterprise to develop and produce Chinese medicine extract granules in China. The company is affiliated to China Traditional Chinese Medicine Holding Co., Ltd., a subsidiary of the world's top 500 companies--Sinopharm. It is the first enterprise to pass the GMP certification of Chinese medicine extract granules in China, and it is an advanced production base of traditional Chinese medicine extract granules.

Tianjiang Pharmaceutical is committed to research and development, production and sales of traditional Chinese medicine extract granules -- an innovative Chinese medicine product. The company focuses on scientific research, has a CNAS accredited national laboratory, the industry's first academician workstation, and a national postdoctoral scientific research workstation.

Tianjiang Pharmaceutical, with the vision of becoming a leader in the standardization, modernization and internationalization of traditional Chinese medicine, will strive to activate the new powder of traditional Chinese medicine. By building a Chinese medicine specialized and disease-specific service platform, integrating, innovating, and enterprising, Tianjiang Pharmaceutical will strive for the great goal of making modern life better with Chinese medicine!





开创精神 A Pioneering Spirit

领跑未来 To Lead The Future

江阴天江药业有限公司 Jiangyin Tianjiang Pharmaceutical Co.,Ltd.

- 江苏省江阴市高新区新胜路1号 NO.1 XIN SHENG ROAD, JIANGYIN CITY,214400, JIANGSU PROVINCE, P.R. CHINA
- 0510-86408692
- www.tianjiang.com



天江官方微信 TIANJIANG OFFICIAL WECHAT